Financial Assistance Programs

Commitment to Patients

For more than 20 years, Sanofi Genzyme has been committed to providing the rare disease community and healthcare providers with personalized support and assistance.

Co-Pay Assistance Program

The Thyrogen Co-Pay Assistance Program assists patients with specific out-of-pocket costs associated with Thyrogen under the patient’s medical and/or pharmacy benefits.

Patient Eligibility

Eligibility Requirements  for the Thyrogen Co-Pay Assistance Program

Who is NOT eligible?

  • Patient must be a US Citizen and have commercial insurance.
  • Patient must have an out-of-pocket obligation that exceeds $100 per kit. (This may include any combination of Co-Pay, Co-Insurance or Deductible.)
  • Eligible patients are responsible for their first $100 of their out-of-pocket; then, the Thyrogen Co-Pay Assistance Program will cover remaining out-of-pocket costs, up to $1,000 per calendar year.
  • Patients with an out-of-pocket responsibility less than $100 per kit.
  • As required by law, the Program is not available to patients covered by federal, state or government funded insurance programs including:
    • Medicare
    • Medicare Advantage Plans
      (Example: FreedomBlue offered through Blue Cross Blue Shield)
    • Medicaid
    • Medigap
    • Veterans Affairs, Department of Defense or TRICARE

How to refer your patients to the co-pay program

Determine eligibility:

  • Complete the ThyrogenONE Prescription Support Enrollment Form
  • Fax the completed form to 1-888-326-1002
  • Questions? Please contact ThyrogenONE at 1-88-THYROGEN (1-888-497-6436). Case Managers are available Monday through Friday, 8:00 AM to 8:00 PM EST.

Does your patient already have a bill?

  • Your patient can contact ThyrogenONE at 1-88-THYROGEN (1-888-497-6436) to discuss co-pay support through the Thyrogen Co-Pay Assistance Program

Important notice: The Thyrogen Co-Pay Assistance Program does not cover prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), or other federal or state programs (including any state prescription drug assistance programs). No claim for reimbursement of any out-of-pocket expense amount covered by the Thyrogen Co-Pay Assistance Program may be submitted to any third party payer, whether public or private.  The Thyrogen Co-Pay Assistance Program is available only in the United States and cannot be combined with any other rebate/coupon, free trial, or similar offer.  Sanofi Genzyme reserves the right to rescind, revoke, or amend this Program without notice.

Patient Assistance Program

The Patient Assistance Program is committed to providing Thyrogen to individuals who:

  • Medically need Thyrogen, and
  • Are uninsured or have  a plan that does not cover Thyrogen

Qualified individuals with well-differentiated thyroid cancer whose physicians have recommended treatment with Thyrogen may be eligible for the Patient Assistance Program. Qualifying patients receive up to two (2) kits of Thyrogen per calendar year.

Learn More

To evaluate patient eligibility for the program, contact ThyrogenONE at 1-88-THYROGEN (1-888-497-6436). Access the Financial Assistance Sheet.

If you have questions please contact ThyrogenONE at 1-88-THYROGEN (1-888-497-6436).

Note: Sanofi Genzyme’s Patient Assistance Program may be discontinued at any time at the discretion of the Patient Assistance Program Committee.

3 ways to access Thyrogen for your patients

  1. Purchase direct from Sanofi Genzyme 
  2. Order through a Specialty Pharmacy
  3. Purchase using a Wholesaler
Learn More »
Reimbursement questions?

Visit the Reimbursement FAQs »

Financial assistance is available for eligible patients

Learn more about our Financial Assistance Programs or download the Financial Assistance Sheet

Questions? Contact a ThyrogenONE case manager at 1-88-THYROGEN (1-888-497-6436)

Additional Information

Depending on the individual insurance plan, Thyrogen may be covered as either a pharmacy or a major medical benefit. Occasionally, additional documentation may be needed in order to obtain prior authorization for coverage and reimbursement of Thyrogen.

Thyrogen® (thyrotropin alfa for injection) 0.9 mg/mL after reconstitution



There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen.

Caution should be exercised in patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, specifically in the elderly and those with a known history of heart disease.

Hospitalization for administration of Thyrogen and post-administration observation in patients at risk should be considered.

There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases.

Patients should be well-hydrated prior to treatment with Thyrogen.

Sudden, rapid and painful enlargement of residual thyroid tissue or distant metastases can occur following treatment with Thyrogen.

Pretreatment with glucocorticoids should be considered for patients in whom tumor expansion may compromise vital anatomic structures.


The most common adverse reactions reported in clinical trials were nausea and headache.


Pregnancy Category C: Animal reproduction studies have not been conducted with Thyrogen. It is also not known whether Thyrogen can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Thyrogen should be given to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Thyrogen is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Results from controlled trials do not indicate a difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those over 65 years of age.

Renal Impairment: Elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels.


Thyrogen is a thyroid stimulating hormone indicated for:

Diagnostic: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations of Use:

  • Thyrogen -stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
  • Even when Thyrogen -Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
  • Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.

Ablation: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitations of Use:

  • The effect of Thyrogen on long term thyroid cancer outcomes has not been determined.

See full Prescribing Information for more details.